Merck, Glaxo to test combo treatment in renal cell carcinoma

Merck (MRK) is set to collaborate with GlaxoSmithKline (GSK) to test a MK-3475 (that's the PD-1 inhibitor)/ pazopanib combo in advanced renal cell carcinoma.

MRK senior VP Iain Dukes says "collaborations like this are central to MRK's strategy to evaluate the potential of MK-3475 for the treatment of cancer."

The companies have initiated a Phase 1/2 trial in treatment naïve patients. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs